Last reviewed · How we verify

NCT05075421

Prognostic Values of Inflammation-based Indices in Gastric Cancer

Completed Last updated 18 March 2022
What this trial tests

trial testing Gastrectomy in Gastric Cancer in 350 participants. Completed in 31 December 2021.

Timeline
1 January 2012
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorGulhane Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date1 January 2012
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gulhane Training and Research Hospital

Who can join

18 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the prognostic values of preoperative inflammation-based indices in patients undergoing potentially curative resection of gastric cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Gastrectomy

Trials testing the same drug.

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other Gulhane Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing